Search

Shanghai Henlius Biotech Anti-CD73 Antibody Patent US12606633B2

The USPTO granted Patent US12606633B2 to Shanghai Henlius Biotech, Inc. on April 21, 2026, covering anti-CD73 antibodies, variants, and antigen binding fragments that bind human CD73 with high affinity and suppress enzymatic activity. The patent includes 17 claims and covers isolated nucleic acid molecules, expression vectors, host cells, and related pharmaceutical compositions for treating subjects.

Anti-TIGIT Antibodies and Usage Method

The European Patent Office published patent application EP4089115A1 titled 'Anti-TIGIT Antibodies and Usage Method' filed by Shanghai Henlius Biotech, Inc. The patent covers anti-TIGIT antibodies and their usage methods, classified under C07K 16/28 with applications in cancer treatment (A61P 35/00). The application designates 34 European member states including DE, FR, GB, IT, ES, NL, and CH.